Phase 2 Clinical Trials
Mid-stage trials that test whether a drug actually works (efficacy) and at what dose, in a few dozen to a few hundred patients.
August 202613
PF-07220060 + PF-07104091 combination dose escalation Phase 2 Est. Readout
Lutetium (177Lu) rhPSMA-10.1 Injection Phase 2 Est. Readout
September 202655
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Phase 2 Est. Readout
Adagrasib oral dose of 400 mg twice daily tablets Phase 2 Est. Readout
October 202632
About Phase 2 Clinical Trials
Phase 2 clinical trials are mid-stage studies — usually dozens to a few hundred patients — designed to establish proof of concept: does the drug produce a clinical effect, at what dose, and with what side-effect profile? They bridge the safety-focused Phase 1 and the confirmatory Phase 3.
Because Phase 2 is the first real test of efficacy in patients with the target disease, its readouts are often the highest-information catalyst in a young company’s life — the moment the market first learns whether the science translates.
Why Phase 2 Trials matter to investors
Phase 2 is statistically the hardest hurdle in drug development — more programs fail here than at any other stage. A clean Phase 2 readout can transform a micro-cap’s valuation and attract partners; a miss frequently ends the program. That asymmetry makes Phase 2 dates a core watch-list catalyst.
Frequently asked questions
What is a Phase 2 clinical trial?
A Phase 2 trial is a mid-stage study in dozens to a few hundred patients that tests whether a drug is effective and identifies the right dose, after Phase 1 established basic safety.
Why are Phase 2 results so important?
Phase 2 is the first genuine test of efficacy in the target disease and has the highest failure rate of any phase, so its readout carries the most new information for investors.
What comes after a successful Phase 2 trial?
Positive Phase 2 data typically leads to an end-of-Phase-2 meeting with the FDA and the design of pivotal Phase 3 trials — and often a financing or partnership.